In This Article:
Last week saw the newest quarterly earnings release from SCHOTT Pharma AG & Co. KGaA (ETR:1SXP), an important milestone in the company's journey to build a stronger business. SCHOTT Pharma KGaA reported in line with analyst predictions, delivering revenues of €230m and statutory earnings per share of €0.19, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on SCHOTT Pharma KGaA after the latest results.
View our latest analysis for SCHOTT Pharma KGaA
Following the latest results, SCHOTT Pharma KGaA's ten analysts are now forecasting revenues of €1.02b in 2025. This would be a reasonable 6.5% improvement in revenue compared to the last 12 months. Per-share earnings are expected to ascend 14% to €1.02. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.03b and earnings per share (EPS) of €1.05 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
The consensus price target held steady at €28.92, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on SCHOTT Pharma KGaA, with the most bullish analyst valuing it at €37.00 and the most bearish at €20.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the SCHOTT Pharma KGaA's past performance and to peers in the same industry. The analysts are definitely expecting SCHOTT Pharma KGaA's growth to accelerate, with the forecast 8.8% annualised growth to the end of 2025 ranking favourably alongside historical growth of 5.4% per annum over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 11% per year. So it's clear that despite the acceleration in growth, SCHOTT Pharma KGaA is expected to grow meaningfully slower than the industry average.